Protalix BioTherapeutics Shares 2026 Strategic Outlook in Letter to Stockholders

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company developing innovative treatments for rare diseases, has issued its annual letter to stockholders outlining its strategic priorities and progress as it enters 2026. The update from President and CEO Dror Bashan highlights a continued focus on building a profitable business alongside a differentiated clinical pipeline addressing high‑need patient populations. A central priority for Protalix is the advancement of PRX‑115, a novel therapy for uncontrolled gout. Early clinical data from the Phase 1 trial show that PRX‑115 delivers a rapid and durable reduction in urate levels with favorable tolerability, supporting its potential as a meaningful new option for patients with poorly controlled disease. Epidemiological data confirm that gout prevalence is rising globally, with unmet treatment needs persisting despite existing therapies. The company is also sharpening its focus on rare kidney diseases, advancing PRX‑119, a long‑acting DNase I designed to reduce inflammation and fibrosis, as part of a renal disease strategy developed through innovation and partnerships. Protalix continues to leverage its partnerships for commercial execution, notably with Chiesi Global Rare Diseases for the launch of Elfabrio® in Fabry disease and with Pfizer Inc. for Elelyso® in Gaucher disease, underpinning revenue stability while supporting long‑term growth. The company also noted ongoing regulatory activity, including efforts to re‑examine a European Medicines Agency opinion on Elfabrio dosing. Overall, Protalix expressed confidence in its foundation of partnership‑driven commercial execution and a purpose‑built pipeline targeting large unmet needs, positioning it for durable growth and long‑term value creation for patients and shareholders alike. #Protalix #RareDiseases #BiotechNews #ClinicalPipeline #SlimScan #GrowthStocks #CANSLIM